AQST Aquestive Therapeutics Inc
Company Analysis
Latest News
🔴 AQST is trading 11.6% down today on FDA deficiencies and fraud litigation overhangs
AQST is trading 11.62% down at $4.41 as the stock faces a renewed selloff tied to FDA-identified deficiencies in its Anaphylm NDA and ongoing securities-fraud...
🔴 AQST is trading 5.6% down today, extending weakness from the previous session
AQST is trading 5.6% down at $4.71 in pre-market, extending the weakness seen in the June 24 after-hours session as regulatory and legal overhangs persist. •...
🔴 AQST makes sharp 11.0% drop
AQST is trading at $4.44, down 11.0% versus the comparison close of $4.99 during after-hours. This is a price-movement alert; no separate company-specific...
🔴 AQST is trading 5.6% down today as a director sells over $125k in stock
• AQST is trading 5.6% down at $4.71 in after-hours sessions following a close of $4.99 on June 24, 2026. • The decline follows news of director Julie Krop...
🟢 Aquestive Therapeutics Inc is trading 5.2% up today on continued momentum and broader market gains
Aquestive Therapeutics Inc is trading 5.2% up at $4.66 on continued recent momentum and a positive broader market backdrop. • No fresh company-specific news,...
🟢 Aquestive Therapeutics Inc is trading 5.6% up today amid a broader market rally and rebound from recent weakness
Aquestive Therapeutics Inc is trading 5.6% up today at $4.21, rebounding from recent weakness and extending this week’s modest gains amid a broader risk-on...
🔴 Aquestive Therapeutics Inc is trading 5.1% down today amid broad market sell-off following strong U.S. jobs data
Aquestive Therapeutics Inc is trading at $3.93 (5.1% down) today, moving broadly in line with a sharp market-wide risk-off slump triggered by...
🟢 AQST is trading 7% up today in thin pre-market trading with no clear catalyst
AQST is trading at $4.30 (+7%) in pre-market sessions, rising from its $4.02 close on May 29, 2026, despite a lack of company-specific news. • The price...
🟢 AQST is trading 7% up today in thin pre-market trading
AQST is trading at $4.30 (+7%) in pre-market session, gapping higher despite no company-specific news or clear catalyst. • The stock rose from its previous...
🟢 AQST is trading 14% up today on a $150M refinancing and positive FDA feedback for Anaphylm
AQST is trading at $4.75 (+14%) as investors react to a $150 million refinancing deal and constructive FDA feedback regarding its Anaphylm treatment. • The...
🔴 AQST is trading 10% down today on profit-taking following a post-earnings rally
AQST is trading at $4.25, down 10% as the stock gives back a portion of yesterday’s double-digit post-earnings gains. * The company reported strong Q1 results...
🔴 AQST is trading 7.1% down today on profit-taking after post-earnings surge
AQST is trading at $4.39 (7.1% down) as investors take profits following a sharp 14.53% rally triggered by strong Q1 earnings results. • The stock surged...
Aquestive Therapeutics Eyes $10 Target, Citing On-Track Anaphylm FDA Filing
Citizens reiterated its Market Outperform rating for Aquestive Therapeutics. The analyst maintained a $10 price target for the stock. Citizens expressed...
🔴 AQST is trading 5.3% down today on profit-taking after earnings-driven rally
AQST is trading about 5.3% down at $4.48 in pre-market, giving back part of its 14.53% surge from the May 14 close at $4.73. • The stock previously jumped...
🟢 AQST is trading 12.83% up today on strong Q1 revenue growth and a $150M refinancing deal
AQST is trading 12.83% up at $4.66 after reporting Q1 2026 revenue of $14.4 million—a 66% year-over-year increase—and announcing a major $150 million...
Aquestive Posts a Blowout Quarter, but Can a Stamp-Sized Allergy Film Justify a Half-Billion-Dollar Bet?
Shares surged 12.8% to $4.66 after Aquestive Therapeutics delivered first-quarter results that caught Wall Street off guard — and not just on revenue. The...
🟢 AQST is trading 12.8% up today on a Q1 earnings beat and 66% revenue growth
AQST is trading at $4.66, up 12.8% today after reporting a 66% year-over-year revenue increase and a significant surge in license and royalty income. • Total...
Aquestive Therapeutics' first quarter revenue grew 66% as it reaffirms plans for a third quarter 2026 Anaphylm NDA resubmission.
Aquestive Therapeutics reported first quarter 2026 revenue of $14.4 million, a 66% increase from the prior year, and a net loss per share of $0.07. The company...
Aquestive Therapeutics Shares Climb Ahead of Q1 Results and Conference Call
Aquestive Therapeutics will report its Q1 2026 financial results and business highlights on May 13, 2026. The company scheduled a follow-up conference call for...